Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Gains from Investment Securities: 2020-2025

Historic Gains from Investment Securities for Nurix Therapeutics (NRIX) over the last 4 years, with Aug 2025 value amounting to $5.8 million.

  • Nurix Therapeutics' Gains from Investment Securities was N/A to $5.8 million in Q3 2025 from the same period last year, while for Aug 2025 it was $9.9 million, marking a year-over-year change of. This contributed to the annual value of $4.1 million for FY2024, which is 82.88% down from last year.
  • According to the latest figures from Q3 2025, Nurix Therapeutics' Gains from Investment Securities is $5.8 million, which was up 105.91% from $2.8 million recorded in Q4 2024.
  • Nurix Therapeutics' Gains from Investment Securities' 5-year high stood at $23.9 million during Q4 2023, with a 5-year trough of -$12.8 million in Q4 2021.
  • Its 3-year average for Gains from Investment Securities is $4.2 million, with a median of $660,500 in 2023.
  • Per our database at Business Quant, Nurix Therapeutics' Gains from Investment Securities plummeted by 103.91% in 2022 and then surged by 5,534.78% in 2024.
  • Over the past 5 years, Nurix Therapeutics' Gains from Investment Securities (Quarterly) stood at -$12.8 million in 2021, then surged by 141.16% to $5.3 million in 2022, then soared by 354.03% to $23.9 million in 2023, then tumbled by 88.25% to $2.8 million in 2024, then reached $5.8 million in 2025.
  • Its last three reported values are $5.8 million in Q3 2025, $2.8 million for Q4 2024, and $1.3 million during Q2 2024.